文献速递甲状腺疾病

立体定向放射外科治疗分化型甲状腺癌脑转移:国际多中心研究

Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study.
PubMed 文献 · Thyroid · 2021-05-11

这项国际多中心研究纳入42例分化型甲状腺癌脑转移患者,共122个病灶接受立体定向放射外科(SRS)治疗。中位生存期14个月,多数患者颅内病灶稳定或缓解,无临床不良放射事件。≥2个脑转移灶和较低Karnofsky功能评分与更短总生存相关。

要点

  • SRS对分化型甲状腺癌脑转移可实现持久局部控制,安全性好。
  • 脑转移灶数量≥2个和SRS时Karnofsky评分较低与更短总生存相关。
  • 局部失败(进展和/或放射性坏死)仅见于4%的病灶。

核心结论

  • SRS使绝大多数乳头状和滤泡状甲状腺癌脑转移患者获得持久局部控制,且不良放射事件风险低。
  • 脑转移灶数量较多和SRS时功能状态较差与更短总生存相关。

研究设计与样本

  • 国际多中心研究,来自国际放射外科研究基金会10家机构。
  • 纳入42例经组织学确诊或影像学怀疑脑转移的乳头状或滤泡状甲状腺癌患者,共122个脑转移灶接受SRS。

主要发现

  • 中位SRS后生存期为14个月(范围3-58个月)。
  • ≥2个脑转移灶患者的总生存显著短于1个脑转移灶患者(Log-rank=5.452,p=0.02)。
  • ≥2个脑转移灶(OR=3.688;CI:1.143-11.904;p=0.03)和SRS时较低Karnofsky功能评分(OR=0.807;CI:0.689-0.945;p=0.008)与更短总生存相关。
  • 中位影像随访25.21±30.49个月,5个(4%)SRS治疗的脑转移灶在SRS后7.2±7.3个月出现局部失败(进展和/或放射性坏死)。
  • 末次影像随访时,有影像资料的患者中33%颅内病变稳定,26%完全缓解,24%部分缓解;无临床不良放射事件。

关键数值与推荐

  • 中位SRS治疗体积为0.79 cm³(范围0.003-38.18 cm³),中位处方剂量为20 Gy(范围8-24 Gy)。
  • 每例患者中位脑转移灶数量为2个(范围1-10个)。
  • SRS时平均年龄59.86±12.69岁,从甲状腺癌诊断至SRS的平均潜伏期为89.05±105.49个月。
  • SRS后7%的脑转移灶出现瘤周T2/FLAIR信号高信号。

临床怎么用

  • 对于分化型甲状腺癌脑转移患者,SRS是可选的局部治疗方式,尤其适用于病灶数量有限者。
  • SRS前应评估脑转移灶数量和Karnofsky功能评分,以辅助预后判断。

局限性

  • 样本量较小(42例患者),为回顾性汇总分析。
  • 部分脑转移灶为影像学怀疑而非组织学确诊。
  • 随访时间变异较大,影像随访数据不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Brain metastases (BM) from differentiated thyroid cancer are rare. Stereotactic radiosurgery (SRS) is commonly used for the treatment of BMs; however, the experience with SRS for thyroid cancer BMs remains limited. The goal of this international, multi-centered study was to evaluate the efficacy and safety of SRS for thyroid cancer BMs. Methods: From 10 institutions participating in the International Radiosurgery Research Foundation, we pooled patients with established papillary or follicular thyroid cancer diagnosis who underwent SRS for histologically confirmed or radiologically suspected BMs. We investigated patient overall survival (OS), local tumor control, and adverse radiation events (AREs). Results: We studied 42 (52% men) patients who underwent SRS for 122 papillary (83%) or follicular (17%) thyroid cancer BMs. The mean age at SRS was 59.86 ± 12.69 years. The mean latency from thyroid cancer diagnosis to SRS for BMs was 89.05 ± 105.49 months. The median number of BMs per patient was 2 (range: 1-10 BMs). The median SRS treatment volume was 0.79 cm3 (range: 0.003-38.18 cm3), and the median SRS prescription dose was 20 Gy (range: 8-24 Gy). The median survival after SRS for BMs was 14 months (range: 3-58 months). The OS was significantly shorter in patients harboring ≥2 BMs, when compared with patients with one BM (Log-rank = 5.452, p = 0.02). Two or more BMs (odds ratio [OR] = 3.688; confidence interval [CI]: 1.143-11.904; p = 0.03) and lower Karnofsky performance score at the time of SRS (OR = 0.807; CI: 0.689-0.945; p = 0.008) were associated with shorter OS. During post-SRS imaging follow-up of 25.21 ± 30.49 months, local failure (progression and/or radiation necrosis) of BMs treated with SRS was documented in five (4%) BMs at 7.2 ± 7.3 months after the SRS. At the last imaging follow-up, the majority of patients with available imaging data had stable intracranial disease (33%) or achieved complete (26%) or partial (24%) response. There were no clinical AREs. Post-SRS peritumoral T2/fluid attenuated inversion recovery signal hyperintensity was noted in 7% BMs. Conclusion: The SRS allows durable local control of papillary and follicular thyroid cancer BMs in the vast majority of patients. Higher number of BMs and worse functional status at the time of SRS are associated with shorter OS in patients with thyroid cancer BMs. The SRS is safe and is associated with a low risk of AREs.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Bunevicius A, Fribance S, Pikis S, et al. Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study. Thyroid. 2021. PMID: 33978475. doi:10.1089/thy.2020.0947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。